

31 MARCH 2017

For professional clients only – not for distribution to retail clients.

#### **Fund Aim**

The fund aims to provide long-term capital growth through investment primarily in Continental European equities.

#### **TOP 10 HOLDINGS** Roche 3.6% Novartis 2. 3.4% 3. Bayer 3.3% 4. **ING Groep** 2.7% 5. Valeo 2.6% 6. SpareBank 1 SMN 2.5% 7. Renault 2.4% 8. **FMC** 2.3% 9. Michelin 2.0% 10. Faurecia 1.9%

## **PERFORMANCE**

	Class B EUR	STOXX Europe 600 ex UK
3 months	7.6%	6.9%
6 months	17.9%	13.6%
12 months	24.6%	17.7%
Since launch (11 Sept. 2015)	21.5%	12.3%

	Class B EUR	STOXX Europe 600 ex UK
2017 YTD	7.6%	6.9%
2016	8.6%	2.4%
2015 (from 11 Sept.)	4.0%	2.6%

## Commentary

In March the Comeragh European Growth Fund posted a positive return of 2.8% vs. a 4.2% return for the STOXX Europe 600 ex UK benchmark. It is always disappointing not to keep pace with the market, but considering that up until March we had enjoyed eight consecutive months of outperformance — dating back to last June — it is not surprising that this streak should end at some stage! We remain ahead of the market on a 3, 6 and 12 month view.


Looking across the portfolio, we would like to highlight that our "alpha" stocks actually outperformed the market – to the tune of 4.6% vs. 4.2%. We were held back this month by our defensive "anchor" stocks, which exist to dampen volatility and are unlikely to keep pace with a strongly rising market. As our April blog piece details, we have approximately 25% of the fund in this section of the portfolio – on the low side for us, given that we do not expect 2017 to be an adverse year for European equities in light of the encouraging macroeconomic picture. Furthermore, we believe that the profile of our alpha stocks offers us ample potential for outperformance over time. With this in mind, it is encouraging to note that our alpha stocks continue to outperform and profit cycles are trending upwards in the context of an ongoing Eurozone recovery. This is widening the valuation "disconnect" on offer and gives us confidence in the outlook for the fund.




31 MARCH 2017

Portfolio activity-wise, we would like to highlight a couple of the disposals this month. Gurit Holding (composite materials) and Implenia (construction) had been in the fund since launch, however following strong performance we have exited both positions. In each case there is still upside to our theoretical fair value but with the valuation discount closing and better profit cycle momentum available elsewhere, these stocks had begun to fall down the rankings on our screening process. The flipside of this is that other stocks enjoying better earnings momentum and with wider valuation discounts have moved towards the top and it is in these areas that we look to recycle capital.

### Sector Allocation



## **Country Allocation**





31 MARCH 2017

### **Risk Overview**

	FUND	INDEX	
P/E	13.8	16.9	
EV/EBITDA	6.5	9.3	
Div Yield	2.9%	3.3%	
ROE	17.7%	16.5%	
3m EPS Revs	4.7%	3.2%	
Net Debt / EBITDA	0.57	0.96	
Sharpe Ratio	1.77		
Beta (3m)	1.01		

### **Fund Facts**

**Fund Status** Sub-fund of a Dublin-domiciled UCITS ICAV, authorised and regulated by the

Central Bank of Ireland. Recognised in the UK by the Financial Conduct

Authority

Sector Europe ex UK

Benchmark Index STOXX Europe 600 ex UK

Fund Size €72.4m

Fund Launch Date 11<sup>th</sup> September 2015

Class	ISIN	SEDOL	Distribution Type	Annual Management Fee	Initial Minimum Subscription
Class A EUR	IE00BYN38431	BYN3843	Income	0.60%	€100,000
Class A GBP Hedged	IE00BYN38985	BYN3898	Income	0.60%	£100,000
Class B EUR	IE00BYN38M12	BYN38M1	Accumulation	0.60%	€100,000
Class B GBP Hedged	IE00BYN38Q59	BYN38Q5	Accumulation	0.60%	£100,000
Class C EUR	IE00BYN38Y34	BYN38Y3	Income	0.75%	€500
Class C GBP Hedged	IE00BYN39629	BYN3962	Income	0.75%	£500
Class D EUR	IE00BYN39B71	BYN39B7	Accumulation	0.75%	€500
Class D GBP Hedged	IE00BYN39C88	BYN39C8	Accumulation	0.75%	£500



31 MARCH 2017

### **Further Information**

Email: info@comeraghcapital.com Website: www.comeraghcapital.com Telephone: +44 (0) 207 381 5022

Dealing:

Daily dealing (except Irish public holidays)11.00 dealing cut-off (forward pricing)

■ 17.00 valuation point

CACEIS Ireland

**+** 353 (0)1 672 1631

One Custom House Plaza, IFSC, Dublin D01 C2C5, Ireland

#### Risk Warning

The value of investments and the income from them can go down as well as up and investors may not receive back the original amount invested. Past performance is not an indicator of future performance. Exchange rates may cause the value of the underlying overseas investments to go down as well as up. Investment in smaller companies may involve a higher degree of risk as markets are usually more sensitive to price movements.

Please read the Risk Section of the Fund's Prospectus and Key Investor Information Document (KIID) for a fuller description of the risks prior to investing. Comeragh Capital LLP and its affiliates and/or their officers, partners and employees may own or have positions in the fund and/or any investment mentioned herein. The factsheet does not represent an invitation to invest in the Fund. Subscriptions must be made in conjunction with the KIID and Prospectus, copies of which can be obtained free of charge in English at <a href="https://www.comeraghcapital.com">www.comeraghcapital.com</a>. Comeragh Capital LLP acts as investment manager and promoter to Comeragh Funds ICAV.